鱼腥草与阿昔洛韦治疗深层单纯疱疹性病毒性角膜炎44例

1996年 3月～ 1998年 3月 ,我们应用鱼腥草结合阿昔洛韦治疗深层单纯疱疹性病毒性角膜炎 44例 ,取得显著疗效。报告如下。一般资料 :选择我科收治深层单纯疱疹性角膜炎 87例 ,男 47例 ,女 40例 ,年龄 16～ 6 5岁。右眼 47例 ,左眼 40例。自发病至我院就诊时间 0 .5～ 3个月 ,病程 30天～ 1.5年不等。患者既往有树枝状角膜炎发作史。查体角膜深层有浸润 ,呈典型盘状角膜病变 ,角膜知觉减退。治疗方法 :将 87例随机分为两组 ,治疗组 44例 ,对照组43例。治疗组用鱼腥草注射液 5 0～ 10 0 ml加入 5 %葡萄糖中静滴 ,每日 1次 ,局部用 0 .1%阿昔洛…     

单纯疱疹病毒性脑炎30例临床特点分析

单纯疱疹病毒性脑炎(HSE)是最常见的散发性、致命性急性病毒性脑炎,国内尚缺乏准确的流行病学资料。1999年1月～2004年10月,我院收治病毒性脑炎98例,其中HSE30例。现结合其临床表现、脑脊液检查及影像学检查分析如下。     

单纯疱疹病毒性脑炎研究进展

单纯疱疹病毒性脑炎(HSE)是常见病,多发病．病情危重,死亡率高,后遗症严重,一直是中枢神经系统病毒感染的研究重点。本文对近年HSE研究进展,包括临床表现和流行病学、动物模型、发病机制、实验室诊断技术、临床治疗等作一综述。     

单纯疱疹性角膜炎123例疗效观察

单纯疱疹性角膜炎(HSK)致盲率极高，传统的药物疗法只是局部点用抗病毒眼药水，对浅层树枝状角膜炎效果比较好，对基质型、内皮型效果较差。1999年6月至2002年8月，我们用阿昔洛韦注射液联合无环鸟苷眼水、类固醇激素加抗生素混合眼水治疗基质型、内皮型HSK，取得较好效果。现报告如下。     

单纯疱疹病毒性脑炎29例的临床观察

目的提高单纯疱疹病毒性脑炎(HSE)的早期诊断和治愈率,减少病死率。方法对29例典型HSE患者临床特点,脑脊液(CSF)检查结果,EEG、影像学、治疗及预后进行回顾性临床分析。结果 HSE患者均呈急性或亚急性起病,首发症状多样多变,临床容易误诊误治,头颅MRI、EEG有利于早期诊断,脑脊液HSV特异性抗体可确诊。结论掌握HSE的临床多变特点,对HSE作出早期诊断及早期有效治疗是改善预后的关键。     

黄菊液雾浴治疗兔实验性单纯疱疹病毒角膜炎研究

目的　证实用黄菊液雾浴法治疗家兔实验性单纯疱疹病毒Ⅰ型 (HSV -Ⅰ )角膜炎的效果。方法　以HSV -Ⅰ感染家兔眼角膜 ,用黄菊液进行雾浴治疗 ,分别用裂隙灯检查和扫描电镜观察病变情况 ,并与对照组比较。结果与结论　治疗组与对照组差别明显 ,黄菊液雾浴治疗单纯疱疹病毒性角膜炎具有良好的效果。     

单纯疱疹病毒性脑炎的研究进展

单纯疱疹病毒性脑炎具有高致残率、高病死率、后遗症严重等特点,本研究围绕单纯疱疹病毒性脑炎中常见因素、实验室检查及常用药物等相关研究进行综述。     

糖皮质激素治疗单纯疱疹病毒性脑炎的临床疗效

目的探讨糖皮质激素治疗单纯疱疹病毒性脑炎的临床疗效。方法选取2012年9月—2013年9月我院收治的单纯疱疹病毒性脑炎患者86例,按照治疗方法不同将其分为试验组51例和对照组35例。对照组患者给予常规对症治疗,试验组患者在此基础上给予糖皮质激素治疗,比较两组患者入院时、治疗后1周(急性期)和治疗后4周(恢复期)T淋巴细胞亚群值变化情况。结果急性期试验组患者CD+4低于对照组(P0.05)。结论在单纯疱疹病毒性脑炎患者发病期给予糖皮质激素治疗能够在短期内有效减轻患者急性炎性反应,改善免疫细胞损伤情况。     

不典型单纯疱疹病毒性脑炎早期诊疗二例

本研究回顾分析我科收治的2例不典型单纯疱疹病毒性脑炎患者的诊治经过,从病因病理特点上分析诊治过程,总结早期诊断及治疗的方法及意义。     

Herpes simplex virus type 1 is the leading cause of genital herpes in New Brunswick

INTRODUCTION:

Little is known about the role of herpes simplex virus (HSV) type 1 (HSV1) in the epidemiology of genital herpes in Canada. Data on herpes viral cultures for two consecutive years obtained from L’Hôpital Dr GL Dumont, which performs all the viral culture testing in New Brunswick, were reviewed. It was hypothesized that HSV1 was the main cause of genital herpes in New Brunswick.

METHODS:

Samples of genital origin sent to the laboratory for HSV culture testing between July 2006 and June 2008 were analyzed. Samples from an unspecified or a nongenital source were excluded from analysis. Multiple positive samples collected from the same patient were pooled into a single sample.

RESULTS:

HSV was isolated from 764 different patients. HSV1 was isolated in 62.6% of patients (male, 55%; female, 63.8%). HSV1 was isolated in 73.2% of patients 10 to 39 years of age and in 32% of patients ≥40 years of age. The difference in rates of HSV1 infection between the 10 to 39 years of age group and the ≥40 years of age group was statistically significant (P<0.001 [χ²]). In a similar Canadian study performed in Nova Scotia, HSV1 was recovered in 53.7% of positive cultures (male, 36.7%; female, 58.1%). The rates of HSV1 infection reported by this study and the present study were significantly different (P<0.001 [χ²] for male, P=0.012 for female).

CONCLUSION:

In New Brunswick, HSV1 is the dominant type of HSV isolated in samples collected from a genital site. Significant rate differences were demonstrated between the groups 10 to 39 years of age and ≥40 years of age.     

Superficial herpes simplex virus wound infection following lung transplantation

Surgical site infections (SSIs) are infections of tissues, organs, or spaces exposed by surgeons during performance of an invasive procedure. SSIs are classified into superficial, which are limited to skin and subcutaneous tissues, and deep. The incidence of deep SSIs in lung transplant (LTx) patients is estimated at 5%. No reports have been published as to the incidence of superficial SSIs specifically in LTx patients. Common sense would dictate that the majority of superficial SSIs would be bacterial. Uncommonly, fungal SSIs may occur, and we believe that no reports exist as to the incidence of viral wound infections in LTx patients, or in any solid organ transplant patients. We report a de novo superficial wound infection with herpes simplex virus following lung transplantation, its possible source, treatment, and resolution.     

Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment

For over one hundred years, viruses have been recognized as capable of killing tumor cells. At present, people are still researching and constructing more suitable oncolytic viruses for treating different malignant tumors. Although extensive studies have demonstrated that herpes simplex virus type 1 （HSV-1） is the most potential oncolytic virus, therapies based on herpes simplex virus type 1 vectors still arouse bio-safety and risk management issues. Researchers have therefore introduced the new idea of treating cancer with HSV-1 mutants labeled with radionuclides, combining radionuclide and oncolytic virus therapies. This overview briefly summarizes the status and mechanisms by which oncolytic viruses kill tumor cells, discusses the application of HSV-1 and HSV-1 derived vectors for tumor therapy, and demonstrates the feasibility and prospect of HSV-1 mutants labeled with radionuclides for treating tumors.     

Non-inflammatory herpes simplex hepatitis in an adult with chronic neutropenia

ABSTRACT— We report the case of a young woman with chronic neutropenia, in whom hepatitis, extensive herpetic eruption and herpes simplex viremia developed after genital herpetic ulceration. Although severe liver necrosis was present, the patient's death did not result from hepatic failure. No inflammatory cell infiltration was found circumscribing the multiple necrotic foci in the liver. This absence of inflammatory cell infiltration reflects the host's inability to normally restrain herpes simplex virus dissemination and, in this patient, might be the consequence of chronic neutropenia.     

Activation and evasion of innate antiviral immunity by herpes simplex virus

Herpes simplex virus (HSV), a human pathogenic virus, has evolved several strategies to evade the production and function of interferons (IFNs) and cytokines generated by the innate immune system to restrict the virus. Equilibrium exists between the virus and the immune response, and a shift in this delicate balance either restricts the virus or enhances virus spread and tissue damage. Therefore, understanding of the cytokine response generated after HSV infection and the underlying virus-cell interactions is essential to improve our understanding of viral pathogenesis. This review summarizes the current knowledge on induction and evasion of the innate immune response by HSV.     

单纯疱疹病毒1型糖蛋白gD的表达纯化及多克隆抗体的制备

目的表达及纯化单纯疱疹病毒1型(Herpes simplex virus type 1,HSV-1)糖蛋白D(glycoprotein D,gD)并制备多克隆抗体。方法双酶切pcDNA 3.1-HSV1-gD和pFastBacTM I质粒,gD基因克隆到pFastBacTM I载体,连接产物转化E.coli DH10Bac感受态细胞并鉴定重组杆状病毒质粒Bacmid-gD。将构建正确的重组杆粒转染Sf9细胞包装杆状病毒。杆状病毒经传代扩增后,诱导重组gD蛋白的表达,使用Ni-NTA亲和层析及凝胶过滤层析纯化重组gD蛋白,进行15%SDS-PAGE电泳鉴定并采用肽指纹图谱分析纯化的gD蛋白。将纯化的gD蛋白进行热稳定性试验检测其在不同缓冲液条件下的稳定性。用重组gD蛋白免疫小鼠,利用ELISA法检测血清抗体滴度。结果成功构建重组质粒pFastBacTM I-gD,转化E.coli DH10Bac感受态细胞后,经蓝白斑筛选鉴定重组杆状病毒质粒Bacmid-gD,鉴定正确的重组质粒感染Sf9细胞,包装出重组杆状病毒,获得滴度为8×108 pfu/ml的P3代杆状病毒。重组杆状病毒再次感染Sf9细胞能够表达高纯度可溶性的重组gD蛋白。不同缓冲液条件下重组gD蛋白稳定性良好。用gD蛋白免疫小鼠,获得ELISA效价为1×105的多克隆抗体。结论成功构建重组杆状病毒质粒Bacmid-gD,表达的HSV-1 gD蛋白稳定及免疫原性良好,制备的抗gD蛋白多克隆抗体滴度高,为HSV-1的亚单位疫苗的制备鉴定了基础。     

Donor-derived fulminant herpes simplex virus hepatitis after liver transplantation: Two cases and review of literature

Background

Fulminant herpetic hepatitis due to herpes simplex virus (HSV), serotype 1 or 2, is a rare but often fatal complication after solid organ transplantation (SOT). HSV hepatitis in SOT recipients can occur either due to primary infection acquired post transplantation, viral reactivation in a seropositive patient, or as donor-derived infection. Cases of fatal hepatitis have been reported in the liver as well as in other SOT recipients. The fatal outcome is mostly due to delayed diagnosis and treatment, which is explained by the lack of clinical specificity of HSV hepatitis.

Methods

We report two cases of fatal donor-derived HSV hepatitis in liver-transplanted recipients. We reviewed all published cases of donor-derived HSV infections after SOT with an evaluation of the presence of prophylaxis and outcome.

Results

In both liver recipients, the retrospective determination of HSV serostatus was negative, and both cases occurred in the absence of cytomegalovirus or HSV prophylaxis. A review of the literature showed a significant series of cases of severe hepatitis, mostly fatal, as well as the absence of specific preventive therapy guidelines in cases of HSV serology mismatch.

Conclusions

The occurrence of two fatal donor-derived hepatitis made the Swiss Transplant Infectious Diseases working group modify its national recommendations regarding pretransplant serostatus determination and HSV prophylaxis after liver transplantation. Further studies are needed to assess this approach.

     

A unique presentation of acute liver failure from herpes simplex virus hepatitis

We present the case of a patient, with history of myelodysplastic syndrome and recent bone marrow transplant, who developed fulminant liver failure secondary to herpes simplex virus (HSV) hepatitis. His presentation was unique, as findings of liver microabscesses on computed tomography scan have not been described previously in this patient population. Despite initial treatment with acyclovir, he continued to deteriorate, and later sensitivities found the HSV strain to be resistant to acyclovir. HSV hepatitis with secondary liver failure is rare and, without appropriate treatment, its mortality is >80%. Early suspicion and immediate therapy are the keys to improve patient survival.